Erste Group Bank Comments on Gilead Sciences FY2026 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Investment analysts at Erste Group Bank upped their FY2026 earnings per share estimates for shares of Gilead Sciences in a research note issued on Thursday, August 27th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will post earnings per share of ($0.45) for the year, up from their previous estimate of ($0.75). The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.50) per share. Erste Group Bank also issued estimates for Gilead Sciences’ FY2027 earnings at $9.86 EPS.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.01 earnings per share.

A number of other research firms have also recently commented on GILD. Needham & Company LLC restated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Weiss Ratings downgraded Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Barclays reduced their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Finally, Truist Financial decreased their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Twenty-four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $158.04.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $146.34 on Tuesday. Gilead Sciences has a 1 year low of $108.46 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The company’s 50-day moving average is $134.68 and its 200 day moving average is $136.50. The stock has a market capitalization of $181.46 billion, a P/E ratio of -54.81 and a beta of 0.32.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of GILD. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences in the 4th quarter worth about $25,000. Persistent Asset Partners Ltd bought a new stake in shares of Gilead Sciences in the second quarter worth approximately $25,000. Kimelman & Baird LLC purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC lifted its position in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the period. Finally, Quattro Advisors LLC purchased a new stake in Gilead Sciences in the fourth quarter worth approximately $26,000. 83.67% of the stock is owned by institutional investors.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $138.36, for a total value of $415,080.00. Following the transaction, the chief financial officer directly owned 165,646 shares of the company’s stock, valued at approximately $22,918,780.56. This represents a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the sale, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 90,000 shares of company stock valued at $12,266,220. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is currently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.